Biotech News

6.25.08 - IBT wins the "Incubator Company of the Year Award" 2008 as Best Life Science Company.

The purpose of the 2008 Maryland Incubator Company of the Year Awards is to publicly recognize achievements by current clients and graduates of Maryland incubators and to provide a forum for the nominees to increase their visibility in the business, technology and investment communities.

Integrated BioTherapeutics, Inc. (IBT) was nominated one of three finalists in the category “Best Life Science Company” this year. During the award ceremony held on June 10th at the Center Club in Baltimore, MD, IBT was announced as the winner of this year’s award. Dr. M. Javad Aman, Founder and Chief Scientific Officer, who received the price, expressed IBT’s appreciation of the assistance received from TEDCO. IBT started its operations with a $50,000 grant from Maryland TEDCO in 2006 and has raised over 9 million dollars in government grants and contracts since then.

This award is in recognition of IBT’s great success over the last 3 years since its establishment in 2005.

- Maryland Incubator Company of the Year - Read Article
- Gazette - Read Article
- Frederick News Post - Read Article
- TechJournal South - Read Article

6.25.2008 - IBT moves to new location

Integrated BioTherapeutics, Inc. will move its laboratory and office space to Germantown, MD. The new location is in the same building as Avalon Pharmaceuticals, 20358 Seneca Meadows Parkway, Germantown, MD 20876. New phone numbers will be posted as soon as they are available. Until then please use the contact form (insert link) for inquiries.

6.25.2008 - IBT receives NIH grant

Integrated BioTherapeutics was awarded a $4.7M from NIH to continue research aimed at development of an immunotherapeutic against one of the toxins of Staphylococcus aureus. The work will be conducted in collaboration with the US Army Medical Research Institute of Infectious Diseases and ABD-Serotec/Morphosys, a German company with expertise in monoclonal antibody production.

Read Article

5.5.2008

Integrated BioTherapeutics has been nominated one of three finalists for the “annual Maryland Incubator Company of the Year Awards” in the category “Life Science Companies”. This category comprises companies involved in the biotechnology or life sciences industry. The awards recognize the achievements of current and graduate companies within Maryland’s incubator network.

Companies are selected based on a number of factors. Criteria considered include:

  • Success in achieving its objectives; its technology or product development
  • Growth in revenue or earnings
  • Number of customers and significant customers
  • Technology transfer
  • Attraction of outside investors
  • Impact on the region
Recipients will be chosen based on their nomination form, onsite visits, and interviews with references. Finalists will have the opportunity to display their products and services at the awards ceremony at the Center Club in Baltimore on June 10, 2008.

View PDF Article

10.1.2007

IBT received a phase I SBIR grant for development of human polyclonal antibody therapeutics against staphylococcal eneterotoxin B (SEB). SEB is classified as a category B select agent by the National Institutes of Health. SEB is also commonly produced by various strains of staphylococcus aureus including certain antibiotic resistant strains. SEB intoxication, as a result of exposure through bioterror dissemination or through natural infection, can cause severe toxic shock and cause incapacitation or death.

Through this project IBT intends to use its proprietary recombinant SEB vaccine (STEBVax) to develop human antibodies in healthy individuals. STEBVax is scheduled to enter into a clinical trial sponsored by National Institute of Allergy and Infectious Diseases (NIAID) in Spring 2008. IBT has entered into a collaborative relationship with Omrix Biopharmaceuticals for development of this therapeutic agent. Through this Phase I SBIR and in close coordination with Omrix Biopharmaceuticals IBT will develop all the required assays and methodologies for development of anti-SEB therapeutic in the Phase II of this SBIR.

7.3.2007

IBT received funding from the Defense Threat reduction Agency (DTRA) to test the safety of IBT's proprietary recombinant vaccine for staphylococcal enterotoxin B (STEBVax). This vaccine will be tested in rhesus monkeys to ensure its safety as a required step before moving into human clinical trials. STEBVax safety will be tested at Bridge Pharmaceuticals, Gaithersburg, MD, according to Good Laboratory Practice (GLP). IBT anticipates completing this study by January 2008 in anticipation of STEBVax clinical trial in Spring 2008.